Tuberculosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Gender and sex differences in occupation-specific infectious diseases: a systematic review.
Tuberculosis and diabetes mellitus: The complexity of the comorbid interactions.
Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q2 2027.
- 12 industry developments reported.
- Q2 2027SSTARLET: Shorter and Safer Treatment Regimens for Latent TB
- Q1 2029A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled Trial
- Q4 2029Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness
- Q1 2030Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)
- Q3 2031Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
Clinical MilestonesViewHide
- 2026-07-24Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)Results expected Q3 2031
- 2026-06-09Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)Results expected Q1 2030
- 2026-05-11SSTARLET: Shorter and Safer Treatment Regimens for Latent TBResults expected Q2 2027
- 2026-05-06Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and EffectivenessResults expected Q4 2029
- 2025-12-01A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled TrialResults expected Q1 2029
- 2026-01-16One-month Latent Tuberculosis Treatment for Renal Transplant CandidatesPrimary completion
- 2025-11-12ANRS 12424: Determination of Adequate Tuberculosis Regimen in Adults and Adolescents Hospitalized With HIV-associated Severe Immune Suppression (CD4 ≤ 100 Cells/µL): the DATURA Trial.Completed
Industry & MarketView all 12Hide
- 2026-09-16[Correspondence] Pragmatic tuberculosis trials must measure what determines implementationTrial news · The Lancet Infectious Diseases
- 2026-10-21Covid-19 and international aid cuts disrupt tuberculosis care in South AfricaIndustry · Clinical Trials Arena
- 2026-10-21Depression, Latent Tuberculosis May Affect RA Drug RetentionIndustry · Medscape Medical News
- 2026-10-01[News] Could Brazil's tuberculosis network detect lung cancer earlier?Industry · The Lancet Oncology
- 2026-09-30Tuberculosis treatment has advanced — now we need to stop drug resistance dragging us backwardsIndustry · Nature News
- 2026-10-21IndustryCovid-19 and international aid cuts disrupt tuberculosis care in South AfricaIndustry · Clinical Trials Arena
- 2026-10-21IndustryDepression, Latent Tuberculosis May Affect RA Drug RetentionIndustry · Medscape Medical News
- 2026-10-01Industry[News] Could Brazil's tuberculosis network detect lung cancer earlier?Industry · The Lancet Oncology
- 2026-09-30IndustryTuberculosis treatment has advanced — now we need to stop drug resistance dragging us backwardsIndustry · Nature News
- 2026-09-23IndustryEvolved enzymes build tuberculosis antibiotic ingredient in the desired form, potentially reducing wasteIndustry · Phys.org — Chemistry
- 2026-09-17IndustryThe impact of heavy metal exposure on drug-induced liver injury in patients with drug-resistant tuberculosisIndustry · Nature — Environmental Sciences
- 2026-09-16Industry[Correspondence] Pragmatic tuberculosis trials must measure what determines implementationTrial news · The Lancet Infectious Diseases
- 2026-08-22IndustryNovel Tuberculosis Vaccine Falls ShortIndustry · MedPage Today — Infectious Disease
- 2026-08-14Industry[Review] Guiding principles for pragmatic randomised trials of tuberculosis treatmentsTrial news · The Lancet Infectious Diseases
- 2026-08-03IndustrySpatial-temporal analysis and influencing factors of pulmonary tuberculosis in Fuzhou, China from 2014 to 2022Industry · Nature — Environmental Sciences
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the t… (2020)
Original application approval — Sirturo is indicated for use as part of an appropriate combination regimen in adult… (2014)
Original application approval — Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary… (2014)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Tuberculosis15
- Mycobacterium tuberculosis9
- Communicable Diseases2
- COVID-192
- Latent Tuberculosis2
- Acquired Immunodeficiency Syndrome1
- Adaptive Immunity1
- B-Lymphocytes1
Leading journals6
- Frontiers in immunology3
- International journal of molecular sciences2
- The European respiratory journal2
- Annals of clinical microbiology and antimicrobials1
- Cell reports1
- Cellular & molecular immunology1
Leading researchers8
- Cirillo DM2
- Goletti D2
- Kampmann B2
- Keane J2
- Migliori GB2
- Zellweger JP2
- Adlhoch C1
- Alffenaar JW1
Affiliations (unnormalised)6
- Yong Loo Lin School of Medicine2
- "L. Spallanzani" National Institute for Infectious Diseases (INMI)1
- Africa Health Research Institute1
- Aga Khan University Hospital1
- Beatrice & Samuel A. Seaver Laboratory1
- Beijing Chest Hospital1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Tuberculosis is an infectious disease caused by species of Mycobacterium tuberculosis in humans and other animals. The literature distinguishes active tuberculosis disease from latent tuberculosis infection, in which infected individuals have no clinical evidence of disease.
Tuberculosis is caused by infection with Mycobacterium tuberculosis. The supplied grounding also notes that disease can remain latent after infection, but it does not support additional causal factors beyond the organism itself.
After inhalation, Mycobacterium tuberculosis is phagocytosed by alveolar macrophages in the lungs. The literature emphasizes host-pathogen interactions, innate immunity, cytokine signaling, and other signal transduction processes in the immune response to infection.
The supplied grounding supports exposure to aerosol droplets containing Mycobacterium tuberculosis as the main risk for transmission. It also indicates that tuberculosis control is more difficult where health services are strained and TB is endemic, but it does not provide specific individual risk factors beyond infection exposure.
Standard care in the supplied grounding centers on diagnosis of active tuberculosis disease and latent tuberculosis infection, along with prevention and control measures. Treatment is described at the level of drug therapy and multidrug regimens, and prevention includes BCG vaccination.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.